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Abstract 
Human immunodeficiency virus type 1 (HIV-1) is a rapidly evolving pathogen and 
causes the acquired immunodeficiency syndrome (AIDS) in humans. There are ~30-35 
million people infected with HIV around the world, and ~25 million have died since the first 
reported cases in 1981. Additionally, each year 2-3 million people become newly infected 
and more than one million die of AIDS. An HIV-1 vaccine would help halt an AIDS 
pandemic, and efforts to develop a vaccine have focused on targeting the HIV-1 envelope, 
Env, found on the surface of the virus. A number of chronically infected individuals have 
been shown to produce antibodies, called broadly neutralizing antibodies (bnAbs), that 
target many strains of HIV-1 by binding to Env, thus suggesting promise for HIV-1 vaccine 
development. BnAbs to take years to develop and have a number of traits that inhibit their 
production; thus, a number of researchers are trying to understand the pathways that 
result in bnAb production so that they can be elicited more rapidly by vaccination. This 
review discusses results and implications from two HIV-1 infected individuals studied 
longitudinally who produced bnAbs against two different sites on HIV-1 Env, and 
immunization studies that used Envs deriving from those individuals. 
Keywords: 
HIV-1, Env, immunogen, epitope, conformation, co-evolution, heterologous neutralization 
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Introduction  
HIV-1, the etiological agent of AIDS, is a rapidly evolving pathogen. The complex 
nature of the HIV envelope, Env, has impeded the development of an effective HIV-1 
vaccine.1 Env is a trimeric gp160 assembly that is processed into gp120 (CD4 receptor-
binding subunit (CD4bs)) and gp41 (transmembrane subunit) by furin cleavage.2 Gp120 
sometimes is “shed”, leaving behind gp41 “stumps”, or other oligomers, which are 
incapable of cell entry3 and can favor the production of strain-specific, or non-neutralizing, 
antibodies.4, 5 An added level of humoral immune evasion stems from the dynamic nature 
of HIV Env and conformational masking.6-12 Upon binding to the host cell receptor CD4, 
gp120 undergoes large conformational changes to an “open” state that permits 
subsequent binding of a co-receptor, triggering further conformational changes and 
ultimately host-cell entry mediated by gp41 rearrangements.13  These different 
conformations of Env present immunodominant epitopes, misdirecting the humoral 
immune response to produce non-protective antibodies.  
HIV also evades the immune system by rapid mutation14, particularly within the five 
variable loops (V1-V5)15, and extensive glycosylation16-18, of Env. V1–V3 are found at the 
apex of the trimer (Fig. 1), and are important for trimer association and cell entry.19, 20 V5 
is found near the CD4 binding site. Env glycosylation, which can be quite heterogeneous 
because of steric effects against glycan processing enzymes21, 22, serves to shield a large 
portion of gp120 since carbohydrate moieties may appear as “self” to the immune system.  
HIV-1 broadly neutralizing antibodies (bnAbs), which target >50% viral variants, are 
produced in up to 25% of infected individuals23-26, suggesting promise for HIV-1 vaccine 
development27. The epitopes of currently identified bnAbs cluster on six predominant 
immunogenic regions on Env28, 29. Moreover, bnAbs develop over a course of at least 4-5 
years of infection. It is now possible to obtain longitudinal virus and antibody sequences 
from HIV-infected donors because of improvements in single B-cell sorting technologies30, 
single-genome amplification and sequencing31 and computational approaches that allow 
the inference of progenitor antibodies32(Fig. 2). These data allow the investigation of virus-
antibody co-evolutionary pathways through the development of bnAbs33-35,13,14 to provide 
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information necessary to develop vaccines to elicit bnAbs along shorter, dominant 
pathways.36 
A number of structural analyses have been performed on HIV-1 bnAb-producing 
donors studied longitudinally33-35, 37, 38, but Envs from only two of those cases have been 
tested in animals (Fig. 2). In this review, we will discuss the two longitudinal cases and the 
related immunization studies. We will focus on lessons learned from the infected donors, 
structural features of the immunogens used, and considerations for future studies.  
HIV-Antibody “Arms Race” Analyses for B-cell Immunogen Design Approaches 
Infection with an HIV transmitted founder (T/F) virus31 causes the immune system 
to produce strain-specific antibodies against the T/F Env.39 The virus “escapes” recognition 
by mutating its Env rapidly. Processes of somatic hypermutation (SHM) and recombination 
in B-cells results in antibodies with a greater affinity for escape virus Envs40, which then 
mutate to yield new escape virus Envs.41 Because they mutate rapidly, most circulating 
viruses are resistant to antibodies from the same time point. These co-evolutionary 
trajectories produce a virus-antibody “arms race”, which in some cases results in 
antibodies that can target heterologous tier-2 (difficult to neutralize) viruses42, 43 and 
bnAbs.  
Understanding the patterns of antibody affinity maturation resulting in bnAb 
development could lead to the design of immunogens that increase the likelihood of 
maturation along the desired, yet disfavored, pathways leading to bnAbs36, 44, 45. A 
vaccination protocol based on a B-cell lineage would prime with one immunogen, and 
boost with a sequence of several different immunogens.46 To do this, one would design 
immunogens with an enhanced affinity for the unmutated common ancestor (UCA)47 and 
intermediate antibodies using their paratopes as structural templates. This relies on 
available structural information – ideally, crystal structures would be determined of the 
complex of the mature antibody Fab with antigen, and of the UCA and one or more 
intermediate antibodies. A structure of a UCA–antigen or intermediate antibody–antigen 
complex would also be helpful, but the native antigen may not bind tightly enough to the 
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UCA to enable structure determination, and thus may require indirect methods to 
determine how to target the UCA.  
CH505: CD4bs bnAb development  
The CH103 Broadly Neutralizing Antibody Lineage 
Liao et al.38 tracked the co-evolution of the CH103 CD4bs bnAb lineage and the 
clade C CH505 HIV-1 Env isolated from an African patient, CH505, starting approximately 4 
weeks after infection through the development of bnAbs. Interestingly, all CH103 lineage 
members, even the UCA, could bind the T/F virus Env. Mutations in the autologous CH505 
virus Env did, however, escape recognition by earlier members of the antibody clonal 
lineage. Moreover, as antibody maturation proceeded, the more mature members of the 
lineage could bind with increasing affinity to heterologous virus Envs.   
The crystal structure of the complex formed between the bnAb CH103 Fab 
fragment and a gp120 outer domain showed that CH103 interacted with the gp120 CD4-
binding loop, V5 loop, and D loop38. The interaction was dominated by the heavy chain 
complementarity determining region (CDR) 3 loop of CH103, which interacts with the 
CD4bs. The UCA CDRH3 loop was more flexible than that of more mature members, which 
likely explains its lack of breadth. To understand affinity maturation, unliganded Fab 
structures were analyzed by superposing heavy-chain variable domains (VH) on that of 
CH103 because the VH domain contacts the conserved CD4 binding loop.
48 The 
superposition showed that during affinity maturation, the orientation of the light-chain 
variable domain (VL) shifted with respect to VH, likely to accommodate gp120 V5 loop 
insertions that occurred during the first year of infection, and which would relieve 
unfavorable contacts with the UCA light chain. The shift was observed between 
intermediate antibodies I3 and I2, which corresponded to the point at which heterologous 
neutralization occurred. Thus, the shift in orientation could account for the ability of 
CH103 bnAbs to bind heterologous Envs with larger V5 loops.  
Results from these studies suggested that binding for a T/F Env to a UCA B-cell 
receptor (BCR) of a bnAb lineage like CH103 can induce bnAbs and be used as a potential 
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starting vaccination immunogen to elicit CD4bs bnAbs. Since several key changes in 
antibodies occurred between the UCA and I3, and between I3 and I2, Envs that bind I3 and 
I2 should be used as boosts to trigger I3- and I2-like antibodies to drive forward a CH103-
like lineage. This bnAb lineage is an especially promising lineage to attempt to mimic via 
sequential vaccination because its natural evolution required fewer mutations compared 
to other CD4bs bnAbs to become broad. 
The CH235 Cooperating Lineage  
Viruses typically mutate to escape immune pressures, but CH103 was observed to 
bind Envs with D-loop mutations more avidly. Why the virus mutated to become more 
sensitive to CH103-lineage antibodies turned out to be the consequence of a 
“cooperating” antibody lineage, called CH235, another bnAb lineage produced in the 
CH505 donor.49, 50 The CH235 and CH103 lineages demonstrated cooperative evolution 
throughout the course of HIV-1 infection: the virus developed an escape mutation in 
response to the CH235 lineage, which drove forward the development of the CH103 bnAb 
lineage. A hallmark of this cooperative evolution is that both antibodies interact at the 
same site on Env to drive their development. 
Unlike CH103, the VH domain of the CH235 lineage antibodies mimicked CD4 
binding to gp120.51, 52 Additionally, unlike CH103, CH235 had very few interactions with 
the V5 loop, but had significant interactions with the D loop49. To compensate for escape 
D-loop mutations, the antibody strengthened its binding to the C4 region, which is on the 
opposite face of gp120. Negative stain EM 3D reconstructions showed that CH235 
members bound to a closed Env trimer with an approach angle similar to that of VRC0153 
and other CD4-mimicking bnAbs.  
Studies from the CH505 donor suggest that an immunization strategy could use the 
CH505 T/F Env to induce naive B-cell responses. The presence of cooperating lineages 
suggests that a strategy for simultaneous induction of CDRH3 and VRC01-class CD4bs 
bnAbs as elicited here, could be to follow up by sequential immunizations using D loop 
mutant Envs. 
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CH505 Immunization Studies 
Williams et al.54 studied the development of HIV-1 targeted antibodies induced by 
vaccination using four CH505 Envs as gp120s: the T/F Env and Envs from weeks 53, 78, and 
100. Sequential immunizations of rhesus macaques (RMs) with the four gp120s in their 
natural order produced the DH522 antibody clonal lineage. This lineage was the most 
similar to that of CH103, but only had autologous tier-1 (neutralization-sensitive), 
heterologous tier-1 and weak heterologous tier-2 neutralization activities.42 A crystal 
structure of the DH522.2 Fab in complex with a gp120 core, together with a superposition 
on the BG505 Env SOSIP.664 (gp140) trimer revealed that the antibody bound to the 
CD4bs in a way that the antibody would clash with a nearby gp120 subunit.54 A negative 
stain EM 3D reconstruction showed that the antibody bound to an open conformation of 
the Env trimer. The inability to bind the closed trimer explains the limited neutralization 
breadth of these clonal lineage members, and suggests that future immunizations should 
use closed trimers, such as disulfide stabilized SOSIPs.29, 55 
In another CH505 immunization study Saunders et al.56 vaccinated rabbits with 
CH505 T/F chimeric SOSIP trimers containing a BG505 gp41 region to help stabilize the 
closed Env conformation.18 Additional Env mutations were included to eliminate exposure 
of V3 loop epitopes and co-receptor binding sites.57 Overall results were better when using 
stabilized CH505 Envs versus non-stabilized ones.56 Rabbits receiving these stabilized Envs 
produced autologous tier-2 neutralizing plasma. Deletion of CD4bs shielding glycans from 
immunogens resulted in more CD4bs antibodies, including ones that could neutralize 
heterologous tier-2 viruses. While the antibody epitope(s) were not determined, these 
studies show the importance of Env stabilization in the induction of tier-2 neutralizing 
antibodies. Moreover, since removing glycans from certain sites on Env could induce larger 
antibody responses58, immunization strategies could use enlarged “glycan hole” Envs as 
primes, and then boost with sequential Envs that have smaller “glycan holes” to 
concentrate the antibody response towards a more desirable site. Some germline-targeted 
trimer-based vaccine approaches have used this approach. For example, others have 
focused on creating glycan holes and changing variable loop lengths and residues around a 
particular epitope on the BG505 SOSIP trimer that was modified to target the germline of 
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the PGT121 glycan supersite bnAb. Knock-in mice immunized by this trimer and boosted 
with successive trimers in which the native surface of Env was gradually restored resulted 
in cross-reactive antibodies 59,60. These results suggest that similar results could be 
achieved with suitable trimers based on lineage studies, such as from CH505. 
Four CH505 Envs from similar time-points were also used in rhesus macaque 
sequential immunization studies conducted by Saunders et al.56 In this case, cleavage 
deficient forms of the gp140 trimer were used, since these were previously shown to be 
immunogenic, and induced low levels of antibodies to certain tier-2 HIV-1 strains in guinea 
pigs61 and in macaques62, 63. One macaque produced tier-2 HIV-1 neutralizing plasma, but 
against the V1V2 region, even though CD4bs-targeting immunogens were used. These 
results demonstrated that V1V2-directed antibodies are more readily induced than those 
against the CD4bs. This is consistent with the fact that CH235.12 had a favorable 
orientation in binding the CD4bs, but still needed high degrees of SHM (>20%) to develop 
breadth49, 50. Studies done in knock-in mice suggest receptor editing and different antibody 
gene usage in macaques versus humans could also inhibit CD4bs bnAbs development.54 
Thus, it may be easier to induce bnAbs against other epitopes. 
CH848: V3-glycan bnAb development  
The DH270 Broadly Neutralizing Antibody Lineage 
V3-glycan bnAbs penetrate the Env glycan “shield” and contact both carbohydrate 
and protein components at the V3 loop base, which includes the highly conserved GDIR 
motif64. These bnAbs require the glycan at N332 for binding and neutralization, and some 
also require other glycans, such as the one at N301. Thus, members of this class of bnAbs 
have different Env footprints65-68. For example, in contrast to other V3-glycan bnAbs, 
DH270-lineage bnAbs have shorter CDRs but are still able to penetrate the glycan shield at 
a different approach angle, as demonstrated by a negative stain EM 3D reconstruction37. 
This binding diversity, together with the limited SHM required for bnAb development 
against this site, suggests that this class of bnAbs may be easier to elicit by a vaccine.  
To better understand V3-glycan bnAb development, the co-evolution of the DH270 
bnAb lineage and the clade C CH848 HIV-1 Env isolated from an African patient, CH848, 
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was analyzed over a 5-year period.36, 69 These studies made use of a synthetic Man9-V3 
glycopeptide, which was designed based on the epitope of the V3-glycan bnAb PGT12867 
and includes both N301 and N332 glycans. It was demonstrated that Man9-V3 structurally 
mimics the V3 region of an intact trimer69 and binds to antibodies with a similar affinity as 
gp120 or trimers69, suggesting its promise for studying antibody-Env interactions, and its 
use as an immunogen. A similar peptide was used to isolate the DH270.6 bnAb and DH475 
cooperating antibody (discussed later) from this patient37. 
In contrast to the CH103 lineage, the DH270 UCA did not bind to the autologous 
T/F virus Env.37 Heterologous breadth and potency of DH270 lineage antibodies increased 
with the accumulation of VH mutations, with improbable mutations playing a critical role 
in affinity maturation.31,59 Improbable mutations are rare events that occur at cold spot 
microsequences71, 72 and once they occur, they are likely to remain fixed in a lineage. 
Crystal structures of DH270.6 and DH270.3, which is less potent/broad, in complex with 
Man9-V3 and the Man9 glycan, respectively, revealed that two low-probability mutations 
were needed for specific anchoring at two complementary positions on Env and therefore 
breadth.65 The G57RH mutation, which occurred early, allowed intermediate IA4 (or a 
precursor) to latch onto the V3 loop backbone near the GDIR motif in a different manner 
from other V3-glycan bnAbs35, 66, 67; the later R98TH mutation in the DH270.6 branch, and 
absent in the DH270.3 branch, relieved the conserved D115H residue from a salt bridge 
within the antibody, so it could bind a high mannose N332 glycan moiety, similar to what 
was observed in other V3-glycan bnAbs35, 67. Thus, repeated immunization with modified 
Envs to select for the improbable mutations, such as G57RH and R98TH, may be essential 
for bnAb induction. 
A challenge in initiating a similar lineage as DH270 by vaccination is the fact that its 
UCA did not bind any sequenced Env trimers or free glycans. The DH270 UCA did, on the 
other hand, bind to the Man9-V3 glycopeptide and its aglycone form (preferential binding 
to the glycopeptide form increased throughout affinity maturation).37 One explanation for 
this is that some altered form of CH848 T/F Env (such as a shed gp120 or fragment of it) 
exposed the V3 loop that stimulated the germline BCR to produce this lineage. This 
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suggests that a possible immunization regimen should start by priming the bnAb UCA with 
the synthetic Man9-V3 glycopeptide, before boosting with an Env trimer. 
The DH272 and DH475 Cooperating Lineages 
DH270 bnAb lineage development was aided by two autologous neutralizing 
cooperating lineages, DH272 and DH475, which also bind the V3-glycan region in an N332 
glycan-dependent manner.37  DH272 and DH475 targeted viruses in the first year and 
selected viral escape mutants that would become sensitive to DH270 bnAb lineage 
members. After 51 weeks, a V1 loop deletion (34 to ~16 V1 loop residues) resulted in a 
switch in neutralization sensitivity from the DH272 and DH475 lineages to the DH270 
lineage. Due to the proximity of the V1 and V3 loops (Fig. 1)73, the V1 loop deletion could 
either alter the conformation of V3, or minimize steric interference that longer V1 loops 
present. There was a restoration of longer V1 loops later in infection and later DH270 
antibodies adapted to viruses with longer V1 loops, similarly to other V3-glycan bnAbs, 
allowing recognition of a broader spectrum of Envs and enhancing breadth.37  
Exactly how DH475 and DH272 bind to Env to cause the escape mutations in V1 has 
yet to be determined, which would guide immunogen design to engage similar responses. 
The action of cooperating lineages for bnAb development suggests that immunogen 
strategies will require multiple Envs and boosting regimens. These results specifically 
suggest that a vaccine regimen should include boosts with Env trimers with progressive V1 
lengths. 
CH848-Related Immunization Studies 
Alam et al.70 and others (unpublished data) are exploring the use of the Man9-V3 
glycopeptide as an immunogen since it was found to interact with the DH270 UCA of 
CH848. Not only would such a peptide mimic the bnAb epitope and bind a germline 
antibody, but it will also minimally present dominant strain-specific epitopes74, suggesting 
promise as an immunogen. Rhesus macaques were immunized with the Man9-V3 
glycopeptide to test whether antibodies against the V3-glycan epitope could be induced.70 
Three antibodies were isolated that could selectively bind Man9-V3 and not its aglycone 
version. Two of these could also bind to CH848 T/F and consensus C gp120s, were sensitive 
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to the presence of the N332 glycan, and relied on high mannose glycans for binding. These 
data showed that Man9-V3 immunization could induce antibody responses against the V3-
glycan bnAb region.  
While the monomeric Man9-V3 glycopeptide is not a potent immunogen, its 
potency could be increased by multimerization of Man9-V3, such as mounting it on a 
nanoparticle as was done for the engineered outer domain targeting B-cell precursors of 
the VRC01 bnAb75 and for the short chain oligosaccharides for producing anti-glycan 
antibodies against Streptococcal challenges. 76 Such multimerization would increase 
multivalency to more effectively increase activation of the necessary B cell pools. 
 It still remains to be determined whether an immunization strategy that primes 
with the Man9-V3 glycopeptide and boosts with trimers would be effective at producing 
bnAbs. A recent study with fusion peptide immunizations followed by boosts with the 
BG505 SOSIP trimer have yielded cross-clade neutralizing responses77, suggesting that a 
similar approach with a V3 glycopeptide may yield promising results as well. The 
antibodies isolated from rhesus macaque immunizations with Man9-V3 have not been 
structurally determined in complex with the glycopeptide or Env, thus it is unknown yet 
whether other considerations are needed when using Man9-V3. Additional structural 
information would help guide such immunization studies. 
Other Considerations 
While the variability of the antibody repertoire among individuals could pose a 
challenge for B-cell immunogen design, for some viral-neutralizing epitopes the relevant 
immunoglobulin repertoire consists of a small number of VH families, suggesting that 
different individuals may produce similar maturation pathways.78, 79 There have also been 
examples of convergent evol-ution of human antibodies, in which antibodies with similar 
gene usage can be isolated from different subjects80-83, or of antibodies that could arise 
with similar CDR structures using different VH families84-88, lending support for longitudinal 
studies in HIV vaccine development. 
Moreover, much of the emphasis in the field has been on elucidating bnAb-Env 
interactions89 and determining changes in antibody structure during affinity maturation.33-
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35, 37, 48 Affinity enhancing mutations in antibodies or virus escape mutations could alter 
thermostability or dynamics90-94, suggesting these features could also play a role in virus-
antibody co-evolution and should be considered in immunogen design strategies. 
Moreover, there is also a lack of Env structures throughout virus evolution and 
glycosylation patterns of T/F Envs may be different from the more difficult to neutralize 
tier-2 and tier-3 Envs.42, 95, 96 Thus, structures of autologous virus Envs throughout their 
evolution should be determined.  
There is also evidence that truncating the Env gp41 tail, as is done for SOSIP 
trimers, can alter the antigenicity of the trimer97, suggesting that use of a full length Env 
may be necessary for structural studies and immunization trials. Together with the use of 
nanodiscs98-100, which will provide a stabilizing environment for the transmembrane region 
of Env, advances in cryo-electron microscopy101-104 and single molecule fluorescence 
microscopy105 are likely to play important roles in structurally characterizing Envs and 
providing insights for immunization trials. 
Conclusions 
A goal of HIV-1 immunogen design is to combine other bnAb specificities to achieve 
a broad coverage of T/F viruses. Additional co-evolution studies, as the ones described 
here, will help provide greater insights to achieve this goal. To account for both B-cell 
ontogeny and co-evolution, it will be important to consider both the conformation of Env 
and the “rate-determining” steps to induce bnAb development via prime-boost regimens. 
Of note, it may not be ideal to study bnAb development in rhesus macaques using human 
derived data, since rhesus macaques do not use the same antibody genes and since 
immunization studies have not yet resulted in bnAbs 62, 106, 107.   Exploring virus-antibody 
co-evolution and performing immunization trials in the same model would help 
circumvent this problem. An example of this would be to study infection in SHIVs108, and 
follow up with immunization trials in rhesus macaques to determine if vaccination could 
result in similar antibodies as those produced in SHIV infections.  
While Env trimers may better mimic the trimer on an intact virion than a 
monomeric gp120 and mask non-neutralizing epitopes, such trimers may not bind to the 
D
ow
nl
oa
de
d 
by
 S
W
A
RT
H
M
O
RE
 C
O
LL
EG
E 
LI
BR
A
RY
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
7/
16
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 13 of 27 
 
 
 
13 
AI
DS
 R
es
ea
rc
h 
an
d 
Hu
m
an
 R
et
ro
vi
ru
se
s 
St
ru
ct
ur
al
 In
sig
ht
s f
ro
m
 H
IV
-A
nt
ib
od
y 
Co
-E
vo
lu
tio
n 
an
d 
Re
la
te
d 
Im
m
un
iza
tio
n 
St
ud
ie
s (
DO
I: 
10
.1
08
9/
AI
D.
20
18
.0
09
7)
 
Th
is 
pa
pe
r h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 co
py
ed
iti
ng
 a
nd
 p
ro
of
 co
rr
ec
tio
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f. 
UCA of a bnAb lineage as was demonstrated by the DH270 UCA. Synthetic peptides that 
interact with the progenitor antibodies and mimic the natural epitope, like the Man9-V3 
glycopeptide, could be used as a prime in such cases. Furthermore, such a synthetic 
immunogen would be helpful in displaying an epitope that might otherwise be a 
heterogeneous in the context of a trimer. Chemical synthesis can overcome this hurdle by 
generating glycopeptides with homogeneous glycosylation patterns109. Moreover, such a 
peptide could present the bnAb epitope without interference from other surface 
features—e.g., the nearby gp120 V1V2 loop, which can interfere with V3 loop recognition. 
The absence of distracting epitopes in Man9-V3 suggests that minimal antigens of this kind 
might be suitable candidate immunogens in regimens involving long-term antigenic 
exposure. To enhance viral clearance, it might be useful to use Man9-V3 in conjunction 
with a monomer containing a T-cell helper epitope, such as a glycoconjugate of the non-
natural pan DR epitope110. Moreover, to improve immunogenicity, the peptide could be 
conjugated to a ligand such as the Toll-like receptor 2 lipopeptide as was described 
elsewhere for a V3-glycopeptide-based immunization study.111 Trimers may be used in 
succession, especially if cooperating lineages recognizing other Env regions are necessary 
for bnAb development. Trimers used in germline-targeted immunization approaches have 
shown promise for inducing cross-reactive antibodies59,60 and thus should be considered in 
lineage-based immunogen design efforts as well. 
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Figure Legends 
 
Figure 1. HIV Env Structure. The receptor-binding gp120 (red) and the transmembrane 
bound gp41 (green), which are targets for vaccine design, are shown as a surface diagram. 
Variable loops (V1V2, V3, and V5) and the CD4bs are colored as indicated in the figure. 
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Figure 2. Scheme of workflow for analyzing HIV-antibody arms races for immunogen 
design purposes. HIV-1 infected donors are recruited and longitudinal sequences of HIV 
and antibodies are determined using single B-cell sorting and Env gene amplification and 
sequencing. Phylogenetic trees are constructed from available sequence data and 
computational approaches, and then structural analysis is done to determine key 
structural changes that might identify rate-limiting steps, important for immunogen 
design. Immunogens are then introduced into vaccinated or infected individuals and the 
process is repeated.  
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